Overview

Post Marketing Observational Study in Patients With Pulmonary Arterial Hypertension

Status:
Completed
Trial end date:
2014-08-01
Target enrollment:
0
Participant gender:
All
Summary
To investigate the long-term safety and effectiveness of Adcirca (tadalafil) in Pulmonary Arterial Hypertension (PAH) patients in the clinical practice -focused topics- 1. To evaluate the incidence of adverse events for the patients with long-term use 2. To evaluate the incidence of adverse events of decreased blood pressure, bleeding (including uterine hemorrhage), visual disturbance and sudden hearing loss.
Accepts Healthy Volunteers?
No
Details
Lead Sponsor:
Eli Lilly and Company
Treatments:
Tadalafil
Criteria
Inclusion Criteria:

- Patients with PAH receiving Adcirca

Exclusion Criteria:Patients who meet the criteria of contraindication

- patients with hypersensitivity to tadalafil

- patients who are using any form of organic nitrate

- patients with severe renal impairment

- patients with severe hepatic impairment

- patients taking strong inhibitors of CYP3A4

- patients taking strong inducers of CYP3A4